ArticleCancer management and research2019

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer.

Liangliang Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.